This compound blocking EphA2 phosphorylation (IC50 = 12 μM) was 4–5 times more efficient compared with LCA (IC50 = 50 μM) in inhibiting prostate cancer cells. This evidence concerns the gene EPHA2 and prostate carcinoma.